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OBJECTIVE
Despite its anti-inflammatory and antiatherogenic effects, adiponectin is poten-
tially associated with adverse clinical outcomes, such as all-cause mortality. As
plasma adiponectin levels are strongly influenced by single nucleotide polymor-
phisms in the gene encoding T-cadherin (CDH13), we conducted a longitudinal
study to investigate the possible link between the CDH13 genotype, plasma adi-
ponectin levels, and all-cause mortality.
RESEARCH DESIGN AND METHODS
This longitudinal study evaluated 2,020 Japanese subjects. Baseline clinical
parameters were obtained from subjects’ personal health records as evaluated at
annual medical check-ups. Plasma high–molecular weight adiponectin (HMWA)
levels were measured by an ELISA assay, and genotyping was performed by a
TaqMan probe assay.
RESULTS
Mean follow-up duration was 6.5 years. Kaplan-Meier analysis showed that
HMWA levels were positively associated with mortality (P < 0.001). HMWA levels
were associated with older age, lower body weight, lower plasma triglyceride and
glucose levels, and higher plasma HDL cholesterol. However, the Cox regression
analysis showed that the positive association between HMWA and all-cause
mortality was independent of these covariates (hazard ratio [HR] 1.92, P = 0.006).
The CDH13 rs4783244 genotype was strongly associated with baseline HMWA
levels (per-allele effect size 1.65 mg/mL, P < 0.001). In a separate analysis by the
CDH13 genotype, the HR for all-cause mortality was linearly increased with the
number of G alleles (P value for HMWA–CDH13 genotype interaction = 0.023).
CONCLUSIONS
Higher plasma HMWA level was an independent prognostic factor for all-cause
mortality in a general population. The CDH13 genotype may be a factor that
affects not only the plasma level of HMWA but also the prognostic significance of
HMWA.
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Adiponectin is an adipocyte-derived
secretory protein that has peripheral
insulin-sensitizing activity (1).
Adiponectin also exerts systemic anti-
inflammatory effects via suppression of
the growth and proliferation of
macrophage progenitors, as well as the
inflammation caused by fully
differentiated macrophages (1).
Further, cross-sectional studies in
various populations have reported
that a higher plasma adiponectin level is
associated with a lower frequency of
type 2 diabetes (2), metabolic syndrome
(3), and thinner carotid arterial wall
thickness (4). The results of these
experimental studies and population-
based cross-sectional association
studies indicate that adiponectin is a
cardioprotective factor in humans.
In contrast, several longitudinal
epidemiological studies have reported
that a higher plasma adiponectin level
was associated with an increased
incidence of cardiovascular disease
(CVD) (5,6) and mortality (7–12). The
underlying mechanism of the inverse
association between these cross-
sectional association studies and
longitudinal prospective studies, the
“adiponectin paradox,” is unclear and
prevents a complete understanding of
the biological role of adiponectin.
A number of possibilities warrant
investigation including reverse causality
stemming from a compensatory increase
of adiponectin to subclinical CVD risks
and adiponectin resistance (13).
Recent advances in DNA array
technology have enabled the high-
throughput analysis of single nucleotide
polymorphisms (SNPs). Genome-wide
association studies (GWAS) have
successfully identified SNPs of the
CDH13 gene that have a strong
association with plasma adiponectin
levels (14,15). The CDH13 gene encodes
T-cadherin, a receptor for hexameric
and high–molecular weight forms of
adiponectin (HMWA) (16). Although
earlier studies (17,18) and recent GWAS
in European subjects (19,20) reported a
strong susceptibility of SNPs in the
ADIPOQ gene that encodes adiponectin,
GWAS of adiponectin in East Asian
subjects, namely Korean (15) and
Japanese (21), identified SNPs in the
CDH13 locus, such as rs4783244.
Because plasma adiponectin levels in
subjects homozygous for the allele that
with an association with higher
adiponectin levels (affected allele) were
;1.5 times higher than those
homozygous for the allele without
(unaffected allele) (21), genetic
variation might be partially involved in
the adiponectin paradox.
To clarify our hypothesis, we analyzed
the possible interaction of the CDH13
genotype in the association of plasma
levels of HMWA and all-cause mortality
in Japanese middle-aged to elderly
community residents.
RESEARCH DESIGN AND METHODS
This longitudinal study enrolled
community-dwelling Japanese subjects
living in Nomura Town, Ehime
Prefecture, a mostly rural town with
11,000 inhabitants. Study subjects were
recruited through a community-based
annual medical check-up process in
2002 as part of the Shimanami Health
Promoting Program (J-SHIPP) (3,22,23),
which was a longitudinal
epidemiological study evaluating factors
relating to CVD, dementia, and death.
Among a total of 2,721 residents who
agreed to participate in the J-SHIPP
study and completed baseline clinical
measurements, 2,020 persons for whom
an overnight fasting plasma sample was
provided (.11 h) for HMWA
measurement (n = 2,084), for whom
CDH13 genotype was determined (n =
2,042), and for whom mortality during
this study period could be followed up
were enrolled in this analysis. All study
procedures were approved by the ethics
committee of Ehime University
Graduate School of Medicine, and all
subjects provided signed informed
consent prior to participation.
Baseline Measurements
Baseline clinical characteristics
evaluated at medical checkups,
including anthropometric
measurements, blood pressure (BP),
and basic plasma markers, were
obtained from personal health records.
Additional characteristics, including
medication and history of CVD, were
obtained by individual interviews
using a structured questionnaire.
Hypertension was defined as any or all
of the following: systolic BP (SBP)$140
mmHg, diastolic BP $90 mmHg, and
current use of antihypertensive
medication. Subjects with a fasting
blood glucose level of .126 mg/dL or
currently using antihyperglycemic
medication were defined as having type
2 diabetes. Renal function was
evaluated based on the estimated
glomerular filtration rate (eGFR), which
was calculated from the plasma
creatinine values using the following
formula specifically developed by the
Japanese Society of Nephrology for the
estimation of the glomerular filtration
rate in Japanese: 1943 creatinine21.0943
age20.2873 0.739 (if female).
Follow-up of All-Cause Mortality
Vital status was ascertained until 30
November 2009 by checking a
residential registration certification,
which is under local government
control. Since the registration of a
person’s death is obligatory under the
Family Registration Law in Japan, the
local government’s vital statistics
database enabled the follow-up of all-
cause mortality. Further, as the
notification of a change of address is
obligatory under the residential
registration certificate system, we were
informed of subjects who moved
outside of the cohort area and treated
them as a censored case.
Measurement of Plasma HMWA Levels
Plasma samples were obtained from
each subject after a period of overnight
fasting of at least 11 h. Samples were
immediately frozen and stored at2808C
until analysis. Plasma concentrations of
HMWA were determined using an ELISA
assay (Fujirebio, Tokyo, Japan) (3,24),
which consisted of HMWA-specific
capture antibody (IH7) and HMWA-
specific horseradish peroxidase–
conjugated detection antibody (POD-IH7).
The specificity of this monoclonal
antibody has previously been
described (25). Standardized HMWA
concentrations were determined by
human HMWA purified by gelatin-
cellulofine column chromatography.
Intra- and interassay coefficient
variations of the adiponectin assaywere
4.4% and 9.7%, respectively.
Genotyping
DNA was extracted from peripheral
blood using a QIAamp DNA blood kit
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(Qiagen, Hilden, Germany). The SNP
rs4783244 in the CDH13 gene was
genotyped by a TaqMan probe assay
using commercially available primers
and probes purchased from the Assay-
on-Demand system (Life Technologies,
Carlsbad, CA). Fluorescence of PCR
products was measured using an ABI
PRISM 7900HT sequence detector (Life
Technologies, Tokyo, Japan).
Statistical Analysis
Differences in the numeric variables of
baseline data were assessed by ANOVA,
and differences in frequency were
assessed by a x2 test. Overall survival
ratio was calculated by Kaplan-Meier
analysis. Covariate-adjusted hazard
ratio (HR) for total mortality was
analyzed by Cox proportional hazards
regression analysis. Combined HR was
calculated under a random effects
model. A P value,0.05 was considered
statistically significant.
RESULTS
Baseline clinical characteristics of study
subjects are shown in Table 1. Mean
HMWA level in female subjects (7.62 6
4.56 mg/mL) was nearly double that in
male subjects (4.12 6 2.93 mg/mL,
P , 0.001). Subjects were therefore
divided by HMWA quartile within each
sex and then combined to avoid
potential sex differences (Table 1).
Table 1 also summarizes the differences
in clinical parameters among HMWA
quartiles. Age was strongly and
positively associated with HMWA
quartile, while BMI showed a significant
inverse association. Plasma levels of HDL
cholesterol, triglyceride, and glucose
were also significantly different among
HMWA quartiles. In a simple comparison,
SBP and eGFR were significantly
associated with HMWA quartile;
however, these associations disappeared
after adjustment for age and BMI.
Mean follow-up duration was 6.5 years,
during which time 84 subjects died.
Figure 1A shows the Kaplan-Meier plot
for all-cause mortality by HMWA
quartile, with the highest quartile being
strongly associated with all-cause
mortality. For clarification of whether
the prognostic significance of HMWA
was independent of possible covariates,
Cox regression analysis was performed
by a forward covariate selection
method. Table 2 summarizes the HR of
the 4th quartile of HMWA, as well as 10
mg/mL increases in HMWA, in relation
to total mortality. In any model adjusted
for relevant clinical parameters (Table 2
[models 1–3]), higher plasma HMWA
levels were independently associated
with total mortality.
The G allele of the CDH13 rs4783244
genotype was strongly associated with
baseline plasma HMWA level (Fig. 2).
Although obese subjects, defined as
having a BMI .25 kg/m2, showed
significantly lower HMWA levels in both
sexes (male obese 3.25 6 2.22,
nonobese 4.49 6 3.12, P , 0.001;
female 6.37 6 3.68, 8.18 6 4.86, P ,
0.001), the association between CDH13
genotype and HMWA was independent
of obesity status (Fig. 2). Per-allele
effect size of the genotype calculated
by a regression analysis adjusted for
age, sex, and BMI was 1.65 mg/mL
(P , 0.001).
Nevertheless, the prognostic
significance of HMWA on total mortality
was independent of the CDH13
genotype (Table 2 [model 4]). In a
separate analysis by the genotype,
however, HR for all-cause mortality was
linearly increased with the number of
G alleles (Fig. 1B), and the association
between HMWA and poor prognosis
was seen only in the GG genotype
carries. The term of interaction between
the CHD13 genotype and plasma HMWA
level was identified as a significant
factor for all-cause mortality (P = 0.023)
in the Cox regression analysis adjusted
for the same covariates as are adjusted
for in model 3 of Table 2. These results
Table 1—Clinical parameters of HMWA quartiles
Total subjects
HMWA quartile P
Quartile 1 Quartile 2 Quartile 3 Quartile 4 ANOVA (crude) Trend (adjusted)
n 2,020 501 507 507 505
HMWA (mg/mL) 6.09 6 4.33 2.34 6 1.07 4.21 6 1.51 6.36 6 2.05 11.43 6 4.60
Age (years) 62.4 6 12.3 57.9 6 11.9 60.9 6 12.4 63.3 6 11.7 67.6 6 11.0 ,0.001
Sex (male %) 44.2 44.3 43.8 43.4 44.2 0.998
BMI (kg/m2) 23.5 6 3.2 24.6 6 3.2 23.8 6 3.2 23.3 6 2.9 22.2 6 3.0 ,0.001
SBP (mmHg) 139 6 22 140 6 22 136 6 21 139 6 23 142 6 22 0.001 0.995
Total cholesterol (mg/dL) 203 6 35 205 6 36 204 6 35 201 6 33 203 6 34 0.302 0.093
HDL cholesterol (mg/dL) 62 6 16 56 6 14 60 6 14 63 6 15 68 6 16 ,0.001 ,0.001
Triglyceride (mg/dL) 113 6 74 139 6 92 115 6 69 107 6 64 91 6 58 ,0.001 ,0.001
eGFR (mL/min/1.73 m2) 80 6 17 82 6 18 80 6 17 81 6 17 78 6 17 ,0.001 0.266
Glucose (mg/dL) 98 6 21 102 6 24 98 6 23 98 6 22 95 6 15 ,0.001 ,0.001
Antihyperglycemic medication (%) 3.4 3.8 2.8 4.1 3.0 0.575
Type 2 diabetes (%) 7.4 10.6 6.9 6.7 5.4 0.011
CDH13 genotype (G allele %) 65.8 51.7 65.3 68.3 77.9 ,0.001
Data are means 6 SD unless otherwise indicated. Quartile of HMWA was calculated within each sex and then combined to avoid potential sex
differences. Statistical significance in numeric variables was assessed by ANOVA, while differences in frequency were assessed by a x2 test. Trends in
numeric variables among the HMWA quartile were assessed by regression analysis adjusted for age and BMI. The eGFR was calculated from plasma
creatinine values using the following formula: 194 3 creatinine21.094 3 age20.287 3 0.739 (if female). Type 2 diabetes was defined as a fasting
plasma glucose level .126 mg/dL or the current use of medication to lower blood glucose levels. G-allele frequency of the CDH13 rs4783244
genotype is shown.
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indicate that the poor prognostic
significance of HMWA was genotype
dependent.
CONCLUSIONS
In this longitudinal study in a general
population, we observed that higher
plasma HMWA levels were significantly
associated with all-cause mortality.
Further, the association between
HMWA and mortality showed a high
degree of variation among CDH13
rs4783244 genotypes. To our
knowledge, this is the first study
showing a genotype-dependent
association of HMWA with all-cause
mortality.
Our results confirmed the increased risk
of all-cause mortality in subjects with a
higher baseline HMWA level. Several
previous studies reported a similar
relationship in general populations (5,
8–10), as well as in patients with type 2
diabetes (7), coronary artery disease
(6,11), and chronic heart failure (12).
Higher plasma HMWA in a general
population is a complex phenotype that
may represent a clustering of subclinical
risk statuses, namely, reduced renal and
cardiac function, obesity, insulin
resistance and metabolic disorders,
atherosclerosis, systemic inflammation,
weight loss in elderly, and anemia.
However, these studies were conducted
mainly in European subjects (7,9–12) or
in European and African American
subjects (5,6,8), with no positive results
being reported from East Asian subjects.
In contrast, it has been reported that the
Japanese population has distinct
anthropometric characteristics,
including a lower frequency of obesity
compared with developed Western
countries (26), and considerably lower
plasma adiponectin levels (27), even in
comparison with Japanese Americans
living in Hawaii (28). In populations with
lower HMWA levels, our results
demonstrate the cross-validity of the
prognostic significance of HMWA.
We also found an inverse association
between HMWA and all-cause mortality
between CDH13 TT and CDH13 GG
genotype carriers, with the HR of the
CDH13 TT genotype failing to reach
statistical significance, presumably due
to the smaller subsample size. Although
the CDH13 gene is known to encode
T-cadherin, a receptor for HMWA, the
functionality of each CDH13 rs4783244
genotype or other unidentified
responsible SNPs in linkage
disequilibrium have not been clarified.
However, T-cadherin knockout mice
were reported to show dramatically
increased plasma adiponectin levels due
to impaired linkage between
adiponectin and target cells (29). It is
therefore possible that the G allele of
the CDH13 genotype causes secondary
hyperadiponectinemina by altering the
amount or functionality of T-cadherin.
This genetically dependent adiponectin
resistance and consequent reduction in
adiponectin’s anti-inflammatory and
antiatherogenic effects may explain the
increased mortality ratio in subjects
with higher HMWA levels. Because
differences in HMWA levels for each
CDH13 rs4783244 genotype were
similar between nonobese and obese
subjects (Fig. 2), the production of
adiponectin and formation of high–
molecular weight isoforms might not
be a factor in the genotype-specific
mortality ratio.
According to the HapMap database
(http://hapmap.ncbi.nlm.nih.gov/),
frequency of the CDH13 rs4783244
genotype is similar across all ethnic
groups. However, GWAS in European
subjects (19,20) identified only the
Figure 1—HMWA and all-cause mortality. A: Kaplan-Meier plot of survival by HMWA quartile
(Q1–Q4). Subjects were divided by HMWA quartile within each sex and then combined to avoid
potential sex differences. B: HR of HMWA with total mortality and CDH13 rs4783244 genotype.
HR of HMWA (continuous variable [per 10 mg/mL]) for each CDH13 rs4783244 genotype was
calculated by a Cox regression analysis adjusted for age and sex. Diamond represents the
combined odds ratio calculated by a random-effects model.
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ADIPOQ gene as susceptible loci for
plasma adiponectin levels. Although
more large-scale GWAS might identify
the CDH13 gene as another susceptible
loci, it is probable that genetic
polymorphisms in the ADIPOQ gene
have a larger effect than those in the
CDH13 genotype in European
populations regardless of the type of
adiponectin complex (30). Because the
ADIPOQ gene encodes adiponectin, our
“genetic adiponectin resistance”
hypothesis involving the CDH13 gene
as a means of explanation might not be
easily extrapolated to other
populations. However, our results
provide novel supporting evidence that
adiponectin resistance is a key
mechanism of the adiponectin paradox,
which is lacking in other proposed
mechanisms such as renal dysfunction
and decreased adiponectin clearance,
weight loss, or sarcopenia in the elderly
and compensatory rise in adiponectin
due to subclinical risks (reverse
causality) (13). Our present results also
excluded the possibility of confounding
effects of decreased renal function.
Several limitations of this study warrant
mention. First, we could not evaluate a
cause-specific mortality, particularly
cardiovascular mortality. Results of
long-term analysis for cardiovascular
mortality would strengthen our
findings. Second, we did not analyze
other molecular isoforms of
adiponectin. As T-cadherin is a receptor
for HMWA and the HMW isoform is
considered an active form, further
investigations regarding isoform
specificity will be necessary. Third, this
study contained ~2,000 study subjects.
Replication studies, particularly in East
Asian populations, with a larger sample
size are therefore needed to confirm our
present findings.
In summary, our longitudinal study
demonstrated that the prognostic
significance of HMWA is genotype
specific. Our findings may provide the
insight necessary to help solve the
adiponectin paradox and further
highlight the importance of genetic
factors in understanding the
contribution of adiponectin levels to
adverse clinical outcomes.
Acknowledgments. The authors thank
Nicholas Crabb and Guy Harris of DMC
Corporation for help in the preparation of the
manuscript.
Funding. This study was supported by a Grant-
in-Aid for Scientific Research from the Ministry
of Education, Culture, Sports, Science and
Technology of Japan; a Science and Technology
Incubation Program in Advanced Regions from
the Japan Science and Technology Agency;
a Grant-in-Aid for Scientific Research from the
Japan Arteriosclerosis Prevention Fund; and a
Research Promotion Award from Ehime
University.
Duality of Interest. No potential conflicts of
interest relevant to this article were reported.
Author Contributions. E.U. and Y.T.
conducted research data acquisition,
statistical analysis, and manuscript writing.
R.K. and H.On. conducted research data
acquisition. K.K. and H.Os. conducted research
data acquisition and contributed to
CONCLUSIONS. T.M. supervised the study. Y.T. is
the guarantor of this work and, as such, had
full access to all the data in the study and takes
responsibility for the integrity of the data and
the accuracy of the data analysis.
Figure 2—Mean HMWA level and CDH13 rs4783244 genotype. Values are means6 SD. Statistical
significancewas assessed by ANOVA.Number of subjects for each genotype is shown in the column.
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Table 2—HR of plasma HMWA levels on total mortality
Model Factors adjusted for
HMWA
10 mg/mL 4th quartile
HR (95% CI) P HR (95% CI) P
1 Age, sex 2.03 (1.34–2.96) 0.001 1.78 (1.19–2.68) 0.006
2 Age, sex, BMI 1.85 (1.20–2.76) 0.006 1.63 (1.08–2.48) 0.021
3 Age, sex, BMI, SBP, TC, HDLC, glucose, CVD, eGFR,
current smoking, current medication
1.91 (1.20–2.96) 0.007 1.59 (1.03–2.46) 0.035
4 Age, sex, BMI, SBP, TC, HDLC, glucose, CVD, eGFR,
current smoking, current medication, CDH13 genotype
1.83 (1.12–2.91) 0.017 1.51 (0.97–2.37) 0.068
HR was calculated by a cox regression analysis. CVD indicates previous history of CVDs (namely, stroke and myocardial infarction). Medication
includes antihypertensive drugs and antihyperglycemic drugs. HDLC, HDL cholesterol; TC, total cholesterol.
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